The Effect of IPD on Lateral Bone Augmentation

NCT06999915 | Not Yet Recruiting

• 1 other identifier: IRAS Project ID: 358068
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

Guided Bone Regeneration (GBR) is a widely used technique during dental implant surgery to help rebuild bone around the implant and improve its long-term appearance and stability. This study investigates whether the amount of bone that regrows depends on a person's original bone shape, known as the Individual Phenotypical Dimension (IPD). The aim is to compare the bone stability and overall results between two approaches: adding bone only up to the original bone line (IPD) or adding bone beyond it (over-contour augmentation). Over the course of a year, the study will assess not only bone and soft tissue healing, but also gum blood flow, implant success, and patient satisfaction. There will be two treatment groups in this study - one group will receive bone grafting just up to their natural bone shape, while the other group will receive a slightly larger graft that extends about 3 mm beyond it. Throughout the study CBCT scans will be taken to assess bone changes around the implant area in order to measure how the bone shape and thickness change over time after surgery.

Conditions

Diagnostic Imaging; Guided Bone Regeneration; Bone Resorption

Outcome Measures

Primary Outcomes (1)

• Linear dimensional (LD) changes of the buccal aspect of the augmented alveolar ridge

  The primary objective is to compare radiographically the differences in the hard tissue stability (linear dimensional changes of the augmented ridge) following guided bone regeneration (GBR) simultaneous to implant placement (IP), when lateral bone augmentation is performed up to Individual Phenotypical Dimension (IPD) (control group) or as an over-contour augmentation beyond IPD (test group).

  baseline, immediately after implant placement (IP) and 12 months after implant loading (IL)

Secondary Outcomes (17)

• Cross-sectional area changes of the buccal aspect of the augmented ridge

  baseline, immediately after IP and 12 months after IL

• Blood flow changes

  baseline, immediately after, and at 1, 3, 7, 15, 30 days after IP

• Soft tissue volume changes

  baseline, immediately after, and at 1, 3, 7, 15, 30 days after IP, immediately after IL, 6 and 12 months after IL

• Extra-oral 3D geometric changes

  baseline, immediately after, 1, 3, 7, 15 and 30 days after IP

• Full mouth plaque score (FMPS)

  baseline, 6 and 12 months after IL

Study Arms (2)

Group 1 (Test Group): IP and GBR as an over-contour augmentation beyond IPD

EXPERIMENTAL

Implant placement and simultaneous guided bone regeneration (GBR) beyond Individual Phenotypical Dimension (IPD). In this group, lateral bone augmentation will be performed as an over-contour augmentation of 3 mm beyond IPD.

Procedure: Group 1 (Test Group): IP and GBR as an over-contour augmentation beyond IPD

Group 2 (Control Group): IP and GBR as a contour augmentation up to IPD

ACTIVE COMPARATOR

Implant placement and simultaneous guided bone regeneration (GBR) up to IPD. In this group, lateral bone augmentation will be performed up to IPD

Procedure: Group 2 (Control Group): IP and GBR as a contour augmentation up to IPD

Interventions

Group 1 (Test Group): IP and GBR as an over-contour augmentation beyond IPD PROCEDURE

In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the test group, bone augmentation will be performed by adding biomaterial 3 mm beyond the Individual Phenotypical Dimension (IPD) to achieve over-contour augmentation. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth.

Group 1 (Test Group): IP and GBR as an over-contour augmentation beyond IPD

Group 2 (Control Group): IP and GBR as a contour augmentation up to IPD PROCEDURE

In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the control group, bone augmentation will be performed by adding biomaterial up to the IPD line in order to achieve a contour augmentation with bone grafting remaining within the boundaries defined by the IPD. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth

Group 2 (Control Group): IP and GBR as a contour augmentation up to IPD

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult (\>18 years old) patients
• Good medical and psychological health
• Engaged patients presenting with a Full Mouth Plaque Score (FMPS) of ≤ 20% within the 6 weeks prior to enrolment
• Need of a tooth/teeth replacement in the incisor, canine or premolar maxillary region that could be provided with an implant-supported fixed prosthesis
• A relatively symmetrical maxillary arch
• A nearly intact contra-lateral alveolar ridge
• At least one neighbouring natural tooth present with healthy periodontal conditions
• After implant placement, presence of a buccal bone dehiscence/ fenestration or buccal bone plate thickness of ≤ 1.5 mm requiring GBR (Monje et al., 2022; Jensen et al.,2023, Group 1 ITI Consensus Report).
• At least 4 weeks of post-extraction socket healing and no ridge preservation prior to implant placement.
• No acute infection at the site; adequate availability of bone apical and palatal to obtain implant primary stability
• A functional occlusion with a minimum of 4 occlusal units (i.e., pairs of occluding posterior teeth)
• Willingness to read and sign a copy of the Informed Consent Form (ICF) after reading the Patient Information Sheet (PIS), and after the nature of the study has been fully explained and potential questions fully answered.

You may not qualify if:

• Any known systemic disease severely affecting bone metabolism (e.g., Cushing's syndrome, Crohn's disease, rheumatoid arthritis, osteoporosis or diabetes type I and uncontrolled diabetes type II).
• Self-reported HIV or other severe immunosuppression.
• Self-reported alcoholism or chronic drug abuse.
• Heavy smokers ( \> 10 cigarettes/day)
• Patients reporting use of vape/e-cigarettes
• Self-reported pregnancy or lactation
• Chronic treatment (i.e., 2 weeks or more) with any medication known to affect oral status or bone metabolism (e.g., bisphosphonates, hormone replacement therapy, immunosuppressants) within 1 month before baseline visit.
• Chronic treatment with anticoagulants (including Aspirin), corticosteroids, immunosuppressants or other medications that may influence blood coagulation/count.
• Untreated caries lesions in neighbouring teeth and untreated/uncontrolled periodontal disease; If patients require periodontal treatment (non-surgical and/or surgical), this will be arranged outside the study protocol and completed prior to enrolment;
• Physical handicaps that would interfere with the ability to perform adequate oral hygiene in the area of implant placement.
• Patients requiring maxillary sinus lift surgery before implant placement or presenting bone dimensions (at any time point of the study) that do not allow implant placement or there is no clinical indication to perform study procedures (i.e. bone augmentation, implant placement).
• Patients not willing to receive animal-derived biomaterials for GBR.
• Patients suffering from a known psychological disorder or with limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.

Sponsors & Collaborators

• University of Belgrade: collaborator
• Queen Mary University of London: lead

Study Sites (1)

Barts Health NHS Trust Dental Hospital

London, E1 1BB, United Kingdom

Location

MeSH Terms

Conditions

Bone Resorption

Condition Hierarchy (Ancestors)

Bone Diseases; Musculoskeletal Diseases

Study Officials

• Nikos Mardas, DDS, MS, PhD

  QMUL

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Miljana Bacevic, DDS, PhD

CONTACT

02078828641; BHNT.Clinicaloralresearchcentre@nhs.net

Nikos Donos, DDS, MS, FHEA, FDSRCSEngl., Ph

CONTACT

BHNT.Clinicaloralresearchcentre@nhs.net

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Masking Details: Due to the nature of the intervention, clinicians performing the surgical intervention and primary outcome examiner will be unblinded. Conversely, participants and researchers analyzing secondary outcomes (e.g., intra-oral \& extra-oral scans, aesthetic scores) will be blinded to treatment allocation throughout the whole study duration.
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2025
• First Posted: May 31, 2025
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): June 1, 2029
• Last Updated: May 7, 2026

Record last verified: 2026-05

Locations

GB (1)